Plasma cell depletion with bortezomib in the treatment of refractory N-methyl-d-aspartate (NMDA) receptor antibody encephalitis. Rational developments in neuroimmunological treatment
© 2018 EAN..
BACKGROUND AND PURPOSE: The aim was to assess the therapeutic potential of bortezomib in the treatment of refractory N-methyl-d-aspartate receptor (NMDAR) antibody encephalitis and its potential in other immune-mediated, B-cell-driven neurological diseases.
METHODS: Two cases of severe NMDAR antibody encephalitis, resistant to first and second line therapy with steroids, intravenous immunoglobulins, plasma exchange, cyclophosphamide and rituximab, were treated with four and five cycles of 1.3 mg/m2 bortezomib at 350 and 330 days following initial presentation.
RESULTS: Both patients showed significant clinical improvement with reductions of NMDAR antibody titres following bortezomib treatment. This is the first case in the literature where the NMDAR antibody level was undetectable following treatment with bortezomib.
CONCLUSION: Bortezomib's unique ability to target long-lived autoreactive plasma cells appears to be a useful adjunct to standard second line immunosuppressive therapy in treatment-refractory NMDAR antibody encephalitis. The drug's pharmacodynamics, cell targeting and mechanism of action are reviewed, and it is postulated that bortezomib may be useful in a host of B-cell-driven neuroimmunological diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
European journal of neurology - 25(2018), 11 vom: 27. Nov., Seite 1384-1388 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Keddie, S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
69G8BD63PP |
|---|
| Anmerkungen: |
Date Completed 16.04.2019 Date Revised 16.04.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ene.13759 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM286762323 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM286762323 | ||
| 003 | DE-627 | ||
| 005 | 20231225052457.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ene.13759 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0955.xml |
| 035 | |a (DE-627)NLM286762323 | ||
| 035 | |a (NLM)30035842 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Keddie, S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Plasma cell depletion with bortezomib in the treatment of refractory N-methyl-d-aspartate (NMDA) receptor antibody encephalitis. Rational developments in neuroimmunological treatment |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.04.2019 | ||
| 500 | |a Date Revised 16.04.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2018 EAN. | ||
| 520 | |a BACKGROUND AND PURPOSE: The aim was to assess the therapeutic potential of bortezomib in the treatment of refractory N-methyl-d-aspartate receptor (NMDAR) antibody encephalitis and its potential in other immune-mediated, B-cell-driven neurological diseases | ||
| 520 | |a METHODS: Two cases of severe NMDAR antibody encephalitis, resistant to first and second line therapy with steroids, intravenous immunoglobulins, plasma exchange, cyclophosphamide and rituximab, were treated with four and five cycles of 1.3 mg/m2 bortezomib at 350 and 330 days following initial presentation | ||
| 520 | |a RESULTS: Both patients showed significant clinical improvement with reductions of NMDAR antibody titres following bortezomib treatment. This is the first case in the literature where the NMDAR antibody level was undetectable following treatment with bortezomib | ||
| 520 | |a CONCLUSION: Bortezomib's unique ability to target long-lived autoreactive plasma cells appears to be a useful adjunct to standard second line immunosuppressive therapy in treatment-refractory NMDAR antibody encephalitis. The drug's pharmacodynamics, cell targeting and mechanism of action are reviewed, and it is postulated that bortezomib may be useful in a host of B-cell-driven neuroimmunological diseases | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a NMDA | |
| 650 | 4 | |a bortezomib | |
| 650 | 4 | |a encephalitis | |
| 650 | 4 | |a neuroimmunology | |
| 650 | 4 | |a plasma cell | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Receptors, N-Methyl-D-Aspartate |2 NLM | |
| 650 | 7 | |a Bortezomib |2 NLM | |
| 650 | 7 | |a 69G8BD63PP |2 NLM | |
| 700 | 1 | |a Crisp, S J |e verfasserin |4 aut | |
| 700 | 1 | |a Blackaby, J |e verfasserin |4 aut | |
| 700 | 1 | |a Cox, A |e verfasserin |4 aut | |
| 700 | 1 | |a Coles, A |e verfasserin |4 aut | |
| 700 | 1 | |a Hart, M |e verfasserin |4 aut | |
| 700 | 1 | |a Church, A J |e verfasserin |4 aut | |
| 700 | 1 | |a Vincent, A |e verfasserin |4 aut | |
| 700 | 1 | |a Zandi, M |e verfasserin |4 aut | |
| 700 | 1 | |a Lunn, M P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of neurology |d 1994 |g 25(2018), 11 vom: 27. Nov., Seite 1384-1388 |w (DE-627)NLM094480362 |x 1468-1331 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2018 |g number:11 |g day:27 |g month:11 |g pages:1384-1388 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ene.13759 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2018 |e 11 |b 27 |c 11 |h 1384-1388 | ||